Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model

British Journal of Pharmacology

Volumn 130, Issue 2, 2000, Pages 231-241

  Inoue, Yoshihiro ^a   Toga, Kazuyuki ^a   Sudo, Toshiki ^a   Tachibana, Kazue ^a   Tochizawa, Shirou ^a   Kimura, Yukio ^a   Yoshida, Yoji ^b   Hidaka, Hiroyoshi ^c,d  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d D Western Therapeutics Institute   (Japan)

Author keywords

Cell proliferation; Cilostamide; Cyclic AMP; Double injury model; Intimal hyperplasia; Phosphodiesterase; Vascular smooth muscle cells

Indexed keywords

CILOSTAMIDE; CYCLIC AMP; PHOSPHODIESTERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BB;

ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; CAROTID ARTERY; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CORONARY STENT; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0034060319     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703287     Document Type: Article

References (56)

1. BAPTISTA, J., UMANS, V.A., DI MARIO, C,. ESCANED, J., DE FEYTER, P. & SERRUYS, P.W. (1995). Mechanism of luminal enlargement and quantification of vessel wall trauma following balloon coronary angioplasty and directional atherectomy. Eur. Heart. J., 16, 1603-1612.
2. BEAVO, J.A., CONTI, M. & HEASLIP, R.J. (1994). Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol., 46, 399-405.
3. BONAN, R., PAIEMENT, P. & LEUNG, T.K. (1996). Swine model of coronary restenosis: effect of a second injury. Cathet. Cardiovasc. Diagn., 38, 44-49.
4. CAPRON, L., JARNET, J., HEUDES, D., MONROSE, D.J. & BRUNEVAL, P. (1997). Repeated balloon injury of rat aorta: A model of neointima with attenuated inhibition by heparin. Arterioscler. Thromb. Vasc. Biol., 17, 1649-1656.
5. CLOWES, A.W. & SCHWARTZ, S.M. (1985). Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ. Res., 56, 139-145.
6. CONTI, M. & JIN, S.L.C. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic. Acid Res. Mol. Biol., 63, 1-38.
7. COOK, S.J. & MCCORMICK, F. (1993). Inhibition by cAMP of Ras-dependent activation of Raf. Science, 262, 1069-1072.
8. DAVIES, H.G. & HAGEN, P.O. (1994). Pathobiology of intimal hyperplasia. Br. J. Surgery, 81, 1254-1269.
9. DAWSON, D.L., CUTLER, B.S., MEISSNER, M.H., STRANDNESS, D.E. (1998). Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation, 98, 678-686.
10. DEGERMAN, E., BELFRAGE, P., NEWMAN, A.H., RICE, K.C. & MANGANIELLO, V.C. (1987). Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J. Biol. Chem., 262, 5797-5807.
11. DREES. M., ZIMMERMANN, R. & EISENBRAND, G. (1993). 3', 5'-cyclic nucleolide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res., 53, 3058-3061.
12. 2+ mobilisation in vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 21, 383-391.
13. FERNS, G.A.A., RAINES, E.W., SPRUGEL, K.H., MOTANI, A.S., REIDY, M.A. & ROSS, R. (1991). Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science, 253, 1129-1132.
14. FINGERLE, J., JOHNSON, R., CLOWES, A.W., MAJESKY, M.W. & REIDY, M.A. (1989). Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc. Natl. Acad. Sci., 86, 8412-8416.
15. FUJISHIGE, K., KOTERA, J., MICHIBATA, H., YUASA, K., TAKEBAYASHI, Si., OKUMURA, K. & OMORI, K. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem., 274, 18438-18445.
16. GERDES, C., FABER-STEINFELD, V., YALKINOUGLU, O. & WOHLFEIL, S. (1996). Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury. Arterioscler. Thromb. Vasc. Biol., 16, 1306-1311.
17. GIMPLE, L.W., GERTZ, S.D., HABER, H.L., RAGOSTA, M., POWERS, E.R., ROBERTS, W.C. & SAREMBOCK, I.J. (1991). Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits. Circulation, 86, 1536-1546.
18. GRAVES, L.M., BORNFELDT, K.E., RAINES, E.W., POTTS, B.C., MACDONALD, S.G., ROSS, R. & KREBS, E.G. (1993). Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A.., 90, 10300-10304.
19. GROVES, P.H., BANNING, A.P., PENNY, W.J., LEWIS, M.J., CHEADLE, H.A. & NEWBY, A.C. (1995). Kinetics of smooth muscle cell proliferation and intimal thickening in a pig carotid model of balloon injury. Atherosclerosis, 117, 83-96.
20. GUERIN, Y., SPAULDING, C., DESNOS, M., FUNCK, F., RAHAL, S., PY, A., BESSE, B., TSOCANAKIS, O., GUERIN, F. & GUEROT, C. (1996). Rotational atherectomy with adjunctive balloon angioplasty versus conventional percutaneous transluminal coronary angioplasty in type B2 lesions; results of a randomized study. Am. Heart J., 131, 879-883.
21. GURUEK, A., DAGALP, Z., ORAL, D., OMURLU, K., CROL, C., AKYOL, T. & TUTAR, E. (1995). Restenosis after transluminal coronary angioplasty: a risk factor analysis. J. Cardiovasc. Risk., 2, 51-55.
22. HIDAKA, H., HAYASHI, H., KOHRI, H., KIMURA, Y., HOSOKAWA, T., IGAWA, T. & SAITOH, Y. (1979). Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J. Pharmacol. Exp. Ther., 211, 26-30.
23. INDOLFI, C., AVVEDIMENTO, E.V., LORENZO, E.D., ESPOSITO, G., RAPACCIUOLO, A., GIULIANO, P., GRIECO, D., CAVUTO, L., STINGONE, A.M., CIULLO, I., CONDORELLI, G. & CHIARIELLO. M. (1997). Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nature Med., 3, 775-779.
24. INOUE, Y., KIMURA, Y., TOCHIZAWA, S., TOGA, K., TACHIBANA, K., YOSHIDA, Y., & HIDAKA, H. (1995). A new model of rat arterial restenosis. -Two stage injury model-. Thromb. Haemostasis., 73, 1335 (Abstract form).
25. INOUE, Y., TOGA, K., TACHIBANA, K., KIMURA, Y. & HIDAKA, H. (1994). Prevention of intimal proliferation by cilostamide. Atherosclerosis, 109, 253 (Abstract form).
26. ISHIZAKA, N., TAGUCHI, J., KIMURA, Y., IKARI, Y., AIZAWA, T., TOGO, M., MIKI, K., KUROKAWA, K. & OHNO, M. (1999). Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis, 142, 41-46.
27. JACKSON, C.L. (1994). Animal models of restenosis. Trench Cardiovasc. Med., 4, 122-130.
28. JORGENSEN, L., GROTHE, A.G., GROVES, H.M., KINLOUGH-RATHBONE, R.L., RICHARDSON, M. & MUSTARD, J.F. (1988). Sequence of cellular responses in rabbit aortas following one and two injuries with a balloon catheter. Br. J. Exp. Path., 69, 473-486.
29. KIMURA, Y., TANI, T., KANBE, T. & WATANABE, K. (1985). Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneim.-Forsch./Drug Res., 35, 1144-1149.
30. KISSANE, J.M. & ROBINS, E. (1958). The fluorometric measurement of deoxyribonucleic acid in animal tissue with special reference to the central nervous system. J. Biol. Chem., 233, 184-188.
31. KOYAMA, H. & REIDY, M.A. (1997). Reinjury of arterial lesions induces intimal smooth muscle cell replication that is not controlled by fibroblast growth factor 2. Circ. Res., 80, 408-417.
32. MANGANIELLO, V.C., TAIRA, M., DEGERMAN, E. & BELFRAGE, P. (1995). Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell. Signal, 7, 445-455.
33. MARX, J. (1993). Two major signal pathways linked. Science, 262, 988-990.
34. MATOUSOVIC, K., GRANDE, J.P., CHINI, C.C.S., CHINI, E.N. & DOUSA, T.P. (1995). Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppresses mitogenesis of rat mesangial cells. J. Clin. Invest., 96, 401-410.
35. MORENO, P.R., BERNARDI, V.H., LOPEZ-CUELLAR, J., NEWELL, J.B., MCMELLON, C., GOLD, U.K., PALACIOS, I.F., FUSTER, V. & FALLON, J.T. (1996). Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation, 94, 3098-3102.
36. 2 in cultured rabbit aortic smooth muscle cells. Atherosclerosis, 71, 165-171.
37. MORISAKI, N., KOYAMA, N., MORI, S., KANZAKI, T., KOSHIKAWA, T., SAITO, Y., YOSHIDA, S. (1989). Effects of smooth muscle cell derived growth factor (SDGF) in combination with other growth factors on smooth muscle cells. Atherosclerosis, 78, 61-67.
38. MULLER, D.W.M., ELLIS, S.G. & TOPOL, E.J. (1992). Experimental models of coronary artery restenosis. J. Am. Coll. Cardiol., 19, 418-432.
39. NIIMI, Y., AZUMA, H. & HIRAKAWA, K. (1994). Repeated endothelial removal augments intimai thickening and attenuates EDRF release. Am. J. Physiol., 266, H1348-H1356.
40. OHLSTEIN, E.H., DOUGLAS, S.A., SUNG, C.P., YUE, T.L., LOUDEN, C., ARLETH, A., POSTE, G., RUFFOLO, R.R. & FEUERSTEIN, G.Z. (1993). Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc. Natl. Acad. Sci., 90, 6189-6193.
41. PAN, X., ARAUZ, E., KRZANOWSKI, J.J., FITZPATRICK, D.F. & POLSON, J.B. (1994). Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDEIII and PDEIV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol., 48, 827-835.
42. ROSS, R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Mature, 362, 801-809.
43. SAREMBOCK, I.J., GERTZ, S.D., GIMPLE, L.W., OWEN, R.M., POWERS, E.R. & ROBERTS, W.C. (1991). Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation, 84, 232-243.
44. SCHWARTZ, L., BOURASSA, M.G., LESPERANCE, J., ALDRIDGE, H.E., KAZIM, F., SALVATORI, V.A., HENDERSON, M., BONAN, R. & DAVID, P.R. (1988). Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. New Engl. J. Med., 318, 1714-1719.
45. SCHWARTZ, S.M., DEBLOIS, D. & O'BRIEN, E.R.M. (1995). The intima. Soil for atherosclerosis and restenosis. Circ. Res.s 77, 445-465.
46. SINGH, J.P., ROTHFUSS, K.J., WIERNICKI, T.R., LACEFIELD, W.B., KURTZ, W.L., BROWN, R.F., BRUNE, K.A., BAILEY, D. & DUBE, G.P. (1994). Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty. J. Am. Coll. Cardiol., 23, 665-671.
47. SOUNESS, J.E., HASSALL, G.A. & PARROTT, D.P. (1992). Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem. Pharmacol., 44, 857-866.
48. STRAUSS, B.H., CHISHOLM, R.J., KEELEY, F.W., GOTLIEB, A.I., LOGAN, R.A. & ARMSTRONG, P.W. (1994). Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ. Res., 75, 650-658.
49. SUDO, T., TACHIBANA, K., TOGA, K., TOCHIZAWA, S., INOUE, Y., KIMURA, Y. & HIDAKA, H. (2000). Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol., 59, 347-356.
50. TSUCHIKANE, E., FUKUHARA, A., KOBAYASI, T., KIRINO, M., YAMASAKI, K., KOBAYASHI, T., IZUMI, M., OTSUJI, S., TATEYAMA, H., SAKURAI, M. & AWATA, N. (1999). Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation, 100, 21-26.
51. TSUCHIKANE, E., KATO, O., SUMITSUJI, S., FUKUHARA, A., FUNAMOTO, M., OTSUJI, S., TATEYAMA, H., AWATA, N. & KOBAYASI, T. (1998). Impact of cilostazol on intimal proliferation after directional coronary atherectomy. Am. Heart. J., 135, 495-502.
52. UMEKAWA, H., TANAKA, T., KIMURA, Y. & HIDAKA, H. (1984). Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography. Biochem. Pharmacol., 33, 3339-3344.
53. VEMULAPALLI, S., WATKINS, R.W., CHINTALA, M., DAVIS, H., AHN, H.S., FAWZI, A., TULSHIAN, D., CHIU, P., CHATTERJEE, M., EIN, C.C. & SYBERTZ, E.J. (1996). Antiplatelct and antiproliferative effects of SCH51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J. Cardiovasc. Pharmacol., 28, 862-869.
54. WOJENSKI, C.M.I. & SILVER, M.J. (1988). Model system to study interaction of platelets with damaged arterial wall. II. inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719. Exp. Mol. Pathol., 48, 116-134.
55. WU, J., DENT, P., JELINEK, T., WOLFMAN, A., WEBER, M.J. & STURGILL, T.W. (1993). Inhibition of the EGF-activated MAP-kinase signaling pathways by adenosine 3', 5'-monophosphate. Science, 262, 1065-1069.
56. XIONG, Y., WESTHEAD, E.W. & SLAKEY, L.L. (1995). Role of phosphodiesterase isoenzymes in regulating intracellular cyclic AMP in adenosine-stimulated smooth muscle cells. Biochem. J., 305, 627-633.